Compare Cytokinetics Inc (CYTK) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Jumia Technologies AG - ADR — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M). The key difference: Cytokinetics Inc is far larger — about 10× Jumia Technologies AG - ADR's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Jumia Technologies AG - ADR for 28 Days on average.
| CYTK | JMIA | |
|---|---|---|
Market Cap | $8.62B | $865.90M |
Volume | 2,594,626 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $14.60 |
52-Week Low | $54.76 | $5.69 |
Typical Hold Time | 19 Days | 28 Days |
Enterprise Value | $8.72B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
JMIA stock trades at $6.48, down 3.86% today, with a bearish technical outlook from moving averages. The company reported Q2 2026 revenue growth and narrowing losses, with a path to EBITDA breakeven by Q4 2026. Analyst consensus is bullish with a $12.00 price target, but the stock faces headwinds from persistent negative earnings and high valuation multiples.
The investment case hinges on JMIA's operational improvements and capital infusion, but risks include sustained cash burn and competitive pressures in African e-commerce. Upside potential exists if profitability targets are met, yet the stock remains speculative given its financial losses and volatile trading pattern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
